PD-L1 (Programmed Death-Ligand 1, also called CD274 or B7-H1) is a key immune checkpoint protein that interacts with PD-1 (Programmed Death-1) to regulate immune responses.
1. What is PD-L1?
- Type: Transmembrane protein (a ligand for PD-1).
- Expressed by:
- Normal cells (e.g., immune cells, epithelial cells) to prevent autoimmunity.
- Cancer cells (to evade immune attack).
- Some viruses and bacteria (to suppress host immunity).
2. How Does PD-L1 Work?
- When PD-L1 binds to PD-1 on T cells, it sends an inhibitory signal, suppressing T-cell activity.
- This interaction helps:
- Prevent excessive immune responses (avoiding autoimmunity).
- Protect healthy tissues from immune attack.
- Allow tumors and pathogens to escape immunity (immune evasion).
3. Role in Cancer (Immune Evasion)
- Many cancers overexpress PD-L1 to deactivate T cells, helping tumors grow unchecked.
- High PD-L1 levels in tumors are often associated with:
- Worse prognosis (more aggressive cancer).
- Better response to PD-1/PD-L1 inhibitor drugs (e.g., pembrolizumab, atezolizumab).
4. PD-L1 in Immunotherapy
- PD-L1 Inhibitors (blocking PD-L1 from binding PD-1):
- Atezolizumab (Tecentriq) – Targets PD-L1 directly.
- Durvalumab (Imfinzi) – Blocks PD-L1/PD-1 interaction.
- Used in cancers like:
- Non-small cell lung cancer (NSCLC).
- Bladder cancer.
- Triple-negative breast cancer.
5. PD-L1 vs. PD-1 Inhibitors
| Feature | PD-L1 Inhibitors | PD-1 Inhibitors |
|---|---|---|
| Target | Block PD-L1 (on tumor/immune cells) | Block PD-1 (on T cells) |
| Example Drugs | Atezolizumab, Durvalumab | Pembrolizumab, Nivolumab |
| Mechanism | Prevent PD-L1 from binding PD-1 | Prevent PD-1 from receiving inhibitory signals |
| Effect | Similar outcome (T-cell reactivation) | Similar outcome (T-cell reactivation) |
6. PD-L1 Testing in Cancer
- Biomarker Testing:
- Tumors are tested for PD-L1 expression levels (via immunohistochemistry, IHC).
- Helps predict response to immunotherapy (higher PD-L1 = better response in some cancers).
- Limitations:
7. Beyond Cancer: PD-L1 in Infections & Autoimmunity
- Chronic Infections (HIV, Hepatitis): Pathogens upregulate PD-L1 to exhaust T cells.
- Autoimmune Diseases: Reduced PD-L1 can lead to unchecked immune attacks (e.g., lupus, rheumatoid arthritis).
Conclusion
PD-L1 is a critical immune checkpoint ligand that helps maintain immune balance but is exploited by cancers to evade destruction. Blocking PD-L1 (or PD-1) has revolutionized cancer treatment, though careful patient selection (via PD-L1 testing) and management of immune-related side effects are essential.
Links